Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 93,705,880
  • Shares Outstanding, K 1,671,230
  • Annual Sales, $ 16,560 M
  • Annual Income, $ 1,565 M
  • 36-Month Beta 0.94
  • Price/Sales 5.07
  • Price/Book 5.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.55 unch
on 01/20/17
60.45 -14.72%
on 01/10/17
-7.57 (-12.80%)
since 12/20/16
3-Month
49.03 +5.14%
on 10/25/16
60.45 -14.72%
on 01/10/17
+1.19 (+2.36%)
since 10/20/16
52-Week
49.03 +5.14%
on 10/25/16
77.12 -33.16%
on 07/15/16
-12.00 (-18.88%)
since 01/20/16

Most Recent Stories

More News
Research and Markets - Global Venous Thromboembolism Drug Forecast and Market Analysis to 2025 Featuring Boehringer Ingelheim, Bayer, Janssen, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo & Portola

Research and Markets has announced the addition of the "PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025" report to their offering.

Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study

--12-month overall survival rates were 26.6% in Opdivo-treated patients compared to 10.9% in placebo-treated patients

Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?

Bristol-Myers (BMY) is set to report fourth-quarter 2016 results on Jan 26. It reported a positive earnings surprise of 18.46% in the last quarter.

The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway

The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway

AstraZeneca Offers Update on Immuno-Oncology Program

AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC.

Research and Markets - Immuno-Oncology Market, 2022: Key Players are Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, and Merck

DUBLIN, Jan 18, 2017 /PRNewswire/ --

Research and Markets - Immuno-Oncology Market, 2022: Key Players are Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, and Merck

Research and Markets has announced the addition of the "Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung,...

Top Research Reports for Microsoft, Biogen & Home Depot

Top Research Reports for Microsoft, Biogen & Home Depot

ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk

On Jan 13, we issued an updated report on ARIAD Pharmaceuticals, Inc. (ARIA).

Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News

The sector was once again slammed by president-elect Donald Trump's comments this week regarding drug pricing.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Support & Resistance

2nd Resistance Point 56.68
1st Resistance Point 56.09
Last Price 51.55
1st Support Level 55.12
2nd Support Level 54.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.